T-cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: Impact on cell motility

Emmanouil Kyriakakis, Kseniya Maslova, Maria Philippova, Dennis Pfaff, Manjunath B. Joshi, Stanislaw A. Buechner, Paul Erne, Thérèse J. Resink

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Genetic and epigenetic studies in different cancers, including cutaneous carcinomas, have implicated T-cadherin (T-cad) as a tumor suppressor. Immunohistochemical and in vitro studies have suggested that T-cad loss promotes incipient invasiveness in cutaneous squamous cell carcinoma (SCC). Molecular mechanisms are unknown. This study found that the main consequence of T-cad silencing in SCC is facilitation of ligand-dependent EGFR activation, whereas T-cad overexpression impedes EGFR activation. Gain- and loss-of-function studies in A431 SCC cells demonstrate T-cad-controlled responsiveness to EGF with respect to pharmacological inhibition of EGFR and to diverse signaling and functional events of the EGFR activation cascade (EGFR phosphorylation, internalization, nuclear translocation, cell retraction/de-adhesion, motility, invasion, integrin Β1, and Rho small GTPases such as RhoA, Rac1, and Cdc42 activation). Further, T-cad modulates the EGFR pathway activity by influencing membrane compartmentalization of EGFR; T-cad upregulation promotes retention of EGFR in lipid rafts, whereas T-cad silencing releases EGFR from this compartment, rendering EGFR more accessible to ligand stimulation. This study reveals a mechanism for fine-tuning of EGFR activity in SCC, whereby T-cad represents an auxiliary "negative" regulator of the EGFR pathway, which impacts invasion-associated behavioral responses of SCC to EGF. This action of T-cad in SCC may serve as a paradigm explaining other malignancies displaying concomitant T-cad loss and enhanced EGFR activity.

Original languageEnglish
Pages (from-to)2275-2285
Number of pages11
JournalJournal of Investigative Dermatology
Volume132
Issue number9
DOIs
Publication statusPublished - 09-2012

Fingerprint

Cell Movement
Squamous Cell Carcinoma
Skin
Chemical activation
Epidermal Growth Factor
Ligands
rho GTP-Binding Proteins
Phosphorylation
Monomeric GTP-Binding Proteins
Skin Neoplasms
Epigenomics
Integrins
H-cadherin
Epithelial Cells
Tumors
Neoplasms
Up-Regulation
Adhesion
Tuning
Pharmacology

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Kyriakakis, Emmanouil ; Maslova, Kseniya ; Philippova, Maria ; Pfaff, Dennis ; Joshi, Manjunath B. ; Buechner, Stanislaw A. ; Erne, Paul ; Resink, Thérèse J. / T-cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma : Impact on cell motility. In: Journal of Investigative Dermatology. 2012 ; Vol. 132, No. 9. pp. 2275-2285.
@article{9134d2f41c3241828856faf27fc2070c,
title = "T-cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: Impact on cell motility",
abstract = "Genetic and epigenetic studies in different cancers, including cutaneous carcinomas, have implicated T-cadherin (T-cad) as a tumor suppressor. Immunohistochemical and in vitro studies have suggested that T-cad loss promotes incipient invasiveness in cutaneous squamous cell carcinoma (SCC). Molecular mechanisms are unknown. This study found that the main consequence of T-cad silencing in SCC is facilitation of ligand-dependent EGFR activation, whereas T-cad overexpression impedes EGFR activation. Gain- and loss-of-function studies in A431 SCC cells demonstrate T-cad-controlled responsiveness to EGF with respect to pharmacological inhibition of EGFR and to diverse signaling and functional events of the EGFR activation cascade (EGFR phosphorylation, internalization, nuclear translocation, cell retraction/de-adhesion, motility, invasion, integrin Β1, and Rho small GTPases such as RhoA, Rac1, and Cdc42 activation). Further, T-cad modulates the EGFR pathway activity by influencing membrane compartmentalization of EGFR; T-cad upregulation promotes retention of EGFR in lipid rafts, whereas T-cad silencing releases EGFR from this compartment, rendering EGFR more accessible to ligand stimulation. This study reveals a mechanism for fine-tuning of EGFR activity in SCC, whereby T-cad represents an auxiliary {"}negative{"} regulator of the EGFR pathway, which impacts invasion-associated behavioral responses of SCC to EGF. This action of T-cad in SCC may serve as a paradigm explaining other malignancies displaying concomitant T-cad loss and enhanced EGFR activity.",
author = "Emmanouil Kyriakakis and Kseniya Maslova and Maria Philippova and Dennis Pfaff and Joshi, {Manjunath B.} and Buechner, {Stanislaw A.} and Paul Erne and Resink, {Th{\'e}r{\`e}se J.}",
year = "2012",
month = "9",
doi = "10.1038/jid.2012.131",
language = "English",
volume = "132",
pages = "2275--2285",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "9",

}

T-cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma : Impact on cell motility. / Kyriakakis, Emmanouil; Maslova, Kseniya; Philippova, Maria; Pfaff, Dennis; Joshi, Manjunath B.; Buechner, Stanislaw A.; Erne, Paul; Resink, Thérèse J.

In: Journal of Investigative Dermatology, Vol. 132, No. 9, 09.2012, p. 2275-2285.

Research output: Contribution to journalArticle

TY - JOUR

T1 - T-cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma

T2 - Impact on cell motility

AU - Kyriakakis, Emmanouil

AU - Maslova, Kseniya

AU - Philippova, Maria

AU - Pfaff, Dennis

AU - Joshi, Manjunath B.

AU - Buechner, Stanislaw A.

AU - Erne, Paul

AU - Resink, Thérèse J.

PY - 2012/9

Y1 - 2012/9

N2 - Genetic and epigenetic studies in different cancers, including cutaneous carcinomas, have implicated T-cadherin (T-cad) as a tumor suppressor. Immunohistochemical and in vitro studies have suggested that T-cad loss promotes incipient invasiveness in cutaneous squamous cell carcinoma (SCC). Molecular mechanisms are unknown. This study found that the main consequence of T-cad silencing in SCC is facilitation of ligand-dependent EGFR activation, whereas T-cad overexpression impedes EGFR activation. Gain- and loss-of-function studies in A431 SCC cells demonstrate T-cad-controlled responsiveness to EGF with respect to pharmacological inhibition of EGFR and to diverse signaling and functional events of the EGFR activation cascade (EGFR phosphorylation, internalization, nuclear translocation, cell retraction/de-adhesion, motility, invasion, integrin Β1, and Rho small GTPases such as RhoA, Rac1, and Cdc42 activation). Further, T-cad modulates the EGFR pathway activity by influencing membrane compartmentalization of EGFR; T-cad upregulation promotes retention of EGFR in lipid rafts, whereas T-cad silencing releases EGFR from this compartment, rendering EGFR more accessible to ligand stimulation. This study reveals a mechanism for fine-tuning of EGFR activity in SCC, whereby T-cad represents an auxiliary "negative" regulator of the EGFR pathway, which impacts invasion-associated behavioral responses of SCC to EGF. This action of T-cad in SCC may serve as a paradigm explaining other malignancies displaying concomitant T-cad loss and enhanced EGFR activity.

AB - Genetic and epigenetic studies in different cancers, including cutaneous carcinomas, have implicated T-cadherin (T-cad) as a tumor suppressor. Immunohistochemical and in vitro studies have suggested that T-cad loss promotes incipient invasiveness in cutaneous squamous cell carcinoma (SCC). Molecular mechanisms are unknown. This study found that the main consequence of T-cad silencing in SCC is facilitation of ligand-dependent EGFR activation, whereas T-cad overexpression impedes EGFR activation. Gain- and loss-of-function studies in A431 SCC cells demonstrate T-cad-controlled responsiveness to EGF with respect to pharmacological inhibition of EGFR and to diverse signaling and functional events of the EGFR activation cascade (EGFR phosphorylation, internalization, nuclear translocation, cell retraction/de-adhesion, motility, invasion, integrin Β1, and Rho small GTPases such as RhoA, Rac1, and Cdc42 activation). Further, T-cad modulates the EGFR pathway activity by influencing membrane compartmentalization of EGFR; T-cad upregulation promotes retention of EGFR in lipid rafts, whereas T-cad silencing releases EGFR from this compartment, rendering EGFR more accessible to ligand stimulation. This study reveals a mechanism for fine-tuning of EGFR activity in SCC, whereby T-cad represents an auxiliary "negative" regulator of the EGFR pathway, which impacts invasion-associated behavioral responses of SCC to EGF. This action of T-cad in SCC may serve as a paradigm explaining other malignancies displaying concomitant T-cad loss and enhanced EGFR activity.

UR - http://www.scopus.com/inward/record.url?scp=84865325177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865325177&partnerID=8YFLogxK

U2 - 10.1038/jid.2012.131

DO - 10.1038/jid.2012.131

M3 - Article

C2 - 22592160

AN - SCOPUS:84865325177

VL - 132

SP - 2275

EP - 2285

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 9

ER -